For over a year, German officials have obstructed one of the Trump administration’s most important reform initiatives. And the president’s patience just ran out.
The White House has repeatedly asked allied countries to roll back their price controls on prescription drugs. If those nations started paying market prices for medicines invented and manufactured in the United States, it would relieve the pressure on American patients, employers, and taxpayers—who are currently forced to fund a disproportionate share of the research and development that benefits the entire world. And it’d boost America’s biotech companies and spur more job-creating research investments.